Le Lézard
Classified in: Health, Business
Subject: PDT

The Kinetix Group Introduces Customer-Centric Hospital Approach in New White Paper


NEW YORK, March 1, 2024 /PRNewswire/ -- The Kinetix Group (TKG) announced the release of its new white paper on optimizing hospital engagement.

According to CMS, the hospital market was estimated at $1.4 trillion in 2022, almost a third of our national healthcare expenditures. However, today's rapidly changing healthcare markets create several challenges for hospitals including financial, leadership, staffing and quality performance.

"To deliver quality, patient-centric care, hospitals must be high-performing stakeholders in the healthcare ecosystem. However, they often face unique challenges on many levels. These challenges create an opportunity for meaningful collaboration with life science companies. A successful partnership requires knowledge of hospital pain points and ability to execute in a changing healthcare landscape. That is where TKG can offer strategic insight and experience for life science leaders," said JP Strapp, managing director and co-author.

"I have seen firsthand the pressures facing provider organizations?particularly staffing and keeping up with performance metrics," said Roxanne McCaffrey, vice president and co-author. "It is important that life science teams understand these dynamics when creating materials to engage stakeholders in these sites. Otherwise, they will struggle to open doors, much less get a seat at the table."

In line with its philosophy to know the customers better than they know themselves, TKG built a three-step, customer-centric approach for life science companies. 

"We are thrilled to showcase TKG's longstanding expertise in the hospital space. Developing a robust hospital access strategy is a critical component of pharma success, and engaging this stakeholder group is more important than ever before," said Anna Sedgwick, vice president and co-author.

To download the white paper, visit here. To learn how TKG can retool your hospital access strategy, contact [email protected] for a capabilities meeting.

The Kinetix Group (TKG) 

The Kinetix Group, a healthcare strategic advisory and marketing agency, is a part of Petauri. TKG empowers life science companies to effectively engage with health system and payer customers. With market access expertise, deep relationships, and connections that span the healthcare ecosystem, TKG is uniquely positioned to understand its clients' customers and design impactful solutions. Its core areas of focus are organized customers, market access, and real-world evidence. To learn more, visit www.thekinetixgroup.com.

SOURCE The Kinetix Group


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: